

Stroke2prevent appoints clinical development manager

Ms. Jolanda van Duinen Msc. joins stroke2prevent

Zwolle, The Netherlands – November 2014, Stroke2prevent BV, an innovative Dutch medical device company, made a key announcement today:

Stroke2prevent has appointed Jolanda van Duinen as manager clinical development. In this newly created position Ms van Duinen will manage a variety of activities to further develop the clinical adaptation of **A-View™**. Responsibilities will include indication development, scientific evidence generation as well as increasing the depth of clinical training programs and marketing communications.

Jolanda van Duinen brings a wide variety of experience in the field of clinical development. After completing a bachelor in Health&Nutrition and obtaining her Masters degree in Health Sciences at the University of Maastricht she gained professional experience in leading companies including Kendle CRO, Abbott International, Campina health nutrition and Polyganics surgical devices.

Chief Executive Officer, Maarten Nibbelke, comments: our clinical development and training programs are cornerstones in our mission; supporting physicians to improve outcomes in cardiac surgery. We welcome Jolanda van Duinen to our team.

About A-View™: A-View is a unique medical device, indicated for use in cardiac surgery and minimal invasive cardiac procedures, including TAVI valve replacement. A-View™ has demonstrated to visualize the atherosclerotic plaque in the aortic arch, being a major cause for stroke by embolism. Post-surgery or post-intervention stroke is a feared treatment complication, significantly impairing quality of life and increasing cost to healthcare. The visual information obtained by using A-View™ enables the surgical team to reduce this embolic stroke risk. This will result in reduced mortality and morbidity in a cost effective fashion.

A-View™ is CE and FDA approved. Following a recent launch at the European Cardio-Thoracic Surgery meeting in Milano, Italy, the product is now commercially available in Europe through a network of selected distribution partners.

For further inquiries: Stroke2prevent BV, Maarten Nibbelke CEO, +31(0)6 22941261 [website](#)